Clinical Trial Update: A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS) [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating tebapivat (AG-946) for anemia in patients with lower-risk myelodysplastic syndromes. The study is currently ACTIVE_NOT_RECRUITIN…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• Tebapivat (tebapivat)

Snippet

Sponsor: Agios Pharmaceuticals, Inc. | Conditions: Myelodysplastic Syndromes | Phase 2 | Status: ACTIVE_NOT_RECRUITING